Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
about
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cellsGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenAdoptive cell transfer: a clinical path to effective cancer immunotherapyFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsAdvances in the treatment of metastatic melanoma: adoptive T-cell therapyQuantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicityStructures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell RecognitionTCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct MechanismsT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingLoss of T Cell Antigen Recognition Arising from Changes in Peptide and Major Histocompatibility Complex Protein Flexibility: IMPLICATIONS FOR VACCINE DESIGNComputational Design of the Affinity and Specificity of a Therapeutic T Cell ReceptorT-cell receptor gene therapy--ready to go viral?Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesCish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceHow (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaT-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaCD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceA universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitroA human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)A practical approach to T-cell receptor cloning and expression.T cell avidity and tumor immunity: problems and solutionsTelomerase and primary T cells: biology and immortalization for adoptive immunotherapy.MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.Specific increase in potency via structure-based design of a TCR.Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen
P2860
Q21559398-0B89D50C-5A38-4BFD-BF88-CEFB90431686Q24623215-F7593771-BBF7-435D-869F-939D1638BE8DQ24644774-BA951830-AD11-449D-A6C1-6DD746106F79Q26865532-83962C33-27A6-4562-89C0-4E167A8CC049Q27027803-E26C03E2-5DB0-403A-94F4-FD8C293C9B43Q27311367-B79183E6-37E1-4DB4-9155-BB331E2CAC3EQ27647534-A20B4A8C-C712-4890-94C0-71ED1EAF7CA2Q27671024-0CD646BE-E4FA-435F-B22C-FA7F5B2BE39CQ27672418-4D280403-AE6A-45D8-82EB-F455764DADA7Q27674375-C80252BD-6656-48A1-8C66-753845E77DFBQ27681832-A93BF75F-FA33-4D9E-9EE0-D2034EA2771CQ28081611-6D7CD5C3-5D2F-4E00-87CD-CFA81310C394Q28085769-FFA303AE-FA2B-4627-BA66-7DC3B4B7C5D7Q28269352-DA912CC3-40D1-4C7D-91C9-FB4052DB45ECQ28727481-4ECE3A14-D8F1-4A6E-A92F-916CD9A465D2Q28749871-E57D86EE-1EFB-4A5C-B7E3-EB8672E0A5EAQ30251555-D2C005AA-1865-4CB9-B705-70A36D3F274CQ30303138-F139CC02-9EA2-4A41-9AF5-1819CEF45D97Q30576352-2DF5EAB3-491B-4624-B21B-5C87C258F817Q30974719-2CD38954-DB2F-4449-9D55-A1A23D9E4225Q33632100-C095EC4B-4906-4A18-9EAF-DFAC75A887E6Q33671654-B7F0B9A7-F2A5-48C3-A21F-521580F57DCCQ33691970-6E81E1B6-9223-4AD7-8A28-2BC29E1F4032Q33737674-8C328355-0E39-4025-9C8E-80464D0AAE8EQ33806306-3004AFB3-65B2-4F3E-A456-C85BE49BC5C8Q33867018-082D73A4-9732-43F5-9AED-B4AC62BAFA12Q33996674-3DECE7CF-9D8E-402A-898E-D921FD1D0681Q34030602-10E61110-A721-4600-8DD0-8BD703239090Q34050163-1015A645-DAC2-4443-ACE5-E8D1B21C1EE6Q34063596-C562CC23-2100-4296-ADB8-87E357D089C6Q34073529-D2FB15B4-05FE-44D9-B433-33F71E7B8128Q34088001-5BAA6CA8-FD6A-413A-8D9A-F7BBA499005EQ34115960-A0F278DA-550F-40C5-8BF6-2B4A52CCEBE3Q34170012-8A86BCE5-AC4E-4C76-972F-FA4C3517A1FCQ34245409-29BD60FA-7F76-4042-ADD8-62F00F125D72Q34347703-BCA7CF28-D799-4EBD-8BA3-7332BBE9F2C9Q34383054-1E96EB52-CFB0-46CC-8154-C9E571500994Q34493886-1647709F-264E-4E1E-9EB6-3664D079413AQ34519488-122E197A-5203-4497-997E-A144C51E6707Q34532116-3C30AB70-FE10-4F5F-A875-D2043AB3BC14
P2860
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@ast
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@en
type
label
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@ast
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@en
prefLabel
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@ast
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@en
P2093
P2860
P1476
Gene transfer of tumor-reactiv ...... umor-infiltrating lymphocytes.
@en
P2093
Bianca Heemskerk
Cyrille J Cohen
Daniel J Powell
Laura A Johnson
Mark E Dudley
Paul F Robbins
Richard A Morgan
Steven A Rosenberg
P2860
P304
P356
10.4049/JIMMUNOL.177.9.6548
P407
P577
2006-11-01T00:00:00Z